2 hours ago
1
koto_feja
IO Biotech (NASDAQ:IOBT) announced on Monday that patients with skin tumors who received its lead cancer vaccine candidate, Cylembio, with Merck’s (NYSE:MRK) anti-PD-1 therapy, Keytruda, lived longer without disease worsening in a late-stage pivotal trial.
Shares of Danish biotech added ~57%
© FBT Company 2025. All rights are reserved
English (US) ·